Zenacts Pharma Pvt Ltd | FAVIVOX FAVIPIRAVIR-400 MG | Favipiravir for COVID-19 treatment | Allopathic Drug Manufacturing

FAVIVOX FAVIPIRAVIR-400 MG

Favipiravir, sold under the brand name 'FAVIVOX FAVIPIRAVIR-400 MG' among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative. Contact Zenacts Pharma Pvt Ltd for franchise / wholesale product inquiry.

Favipiravir for COVID-19 treatment

Considering the approved status, evidence on the safety and key indicators of efficacy of favipiravir in COVID-19 from trials/registries in Russia, Japan, China, and Thailand, it appears to be useful in the management of COVID-19, particularly mild to moderate disease; however, large randomized controlled trials are required to demonstrate whether this effect translates to clinical benefits like shortening the disease course, early hospital discharge, and reducing the need for oxygen requirement. It is now commercialized in many countries like Russia, Bangladesh, Pakistan, Jordan, Egypt, and Saudi Arabia for COVID-19 treatment. The rapid viral clearance, higher clinical recovery rate, and availability as an oral drug with proven safety profile makes it the promising drug, repurposed to treat COVID-19. The worldwide ongoing clinical studies on favipiravir will further provide more insights on its clinical efficacy, safety, and therapeutic place in the overall management of COVID-19. Contact Zenacts Pharma Pvt Ltd for franchise / wholesale product inquiry.